2. Academic Validation
  3. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

  • Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.
Khan Sharun 1,  Kuldeep Dhama 2,  Shailesh Kumar Patel 3,  Mamta Pathak 3,  Ruchi Tiwari 4,  Bhoj Raj Singh 5,  Ranjit Sah 6,  D Katterine Bonilla-Aldana 7 8,  Alfonso J Rodriguez-Morales 9 10,  Hakan Leblebicioglu 11
Affiliations

Affiliations

  • 1 Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
  • 2 Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India. kdhama@rediffmail.com.
  • 3 Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
  • 4 Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU), Mathura, 281001, India.
  • 5 Division of Epidemiology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
  • 6 Department of Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
  • 7 Semillero de Zoonosis, Grupo de Investigación BIOECOS, Fundación Universitaria Autónoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia.
  • 8 Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia.
  • 9 Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia. arodriguezm@utp.edu.co.
  • 10 Faculty of Medicine, Grupo de Investigacion Biomedicina, Fundacion Universitaria Autonoma de las Americas, Pereira, Risaralda, Colombia. arodriguezm@utp.edu.co.
  • 11 Department of Infectious Diseases, Samsun Liv Hospital, Samsun, Turkey.
PMID: 32473642 DOI: 10.1186/s12941-020-00368-w
Keywords

2019-nCoV; COVID-19; Coronavirus; Ivermectin; SARS-CoV-2; Therapeutics.

Figures
Products